# Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

> **NCT05542342** · PHASE2 · COMPLETED · sponsor: **Grupo Español Multidisciplinar de Melanoma** · enrollment: 16 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Sitravatinib Malate

## Key facts

- **NCT ID:** NCT05542342
- **Lead sponsor:** Grupo Español Multidisciplinar de Melanoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-23
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-05-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05542342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05542342, "Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05542342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*